Adocia (ADOIF) Stock Price, News & Analysis

Company Overview

Adocia is a clinical-stage biotechnology company headquartered in Lyon, France, specializing in the development of innovative formulations of therapeutic proteins for metabolic diseases. The company’s core focus lies in enhancing the pharmacological properties of protein-based hormones—particularly insulin and GLP-1 analogs—through its proprietary BioChaperone® platform, which aims to improve stability, solubility and controlled release profiles. Adocia’s pipeline includes several candidate products designed to address insulin management, obesity and related metabolic disorders.

The BioChaperone® technology platform leverages small molecule excipients that form reversible, noncovalent complexes with therapeutic proteins, enabling rapid onset, extended duration or co-formulation of multiple hormones. Key programs include ultra-rapid insulin formulations intended to mimic physiological insulin secretion and combination therapies pairing insulin with GLP-1 analogs to support both glycemic control and weight management. Adocia has entered strategic collaborations and licensing agreements with pharmaceutical partners, notably signing a deal with Eli Lilly for the preclinical development of obesity treatments based on the BioChaperone® technology.

Founded in 1997, Adocia has evolved from an early-stage research outfit into a publicly traded entity on Euronext (with an American Depositary Receipt listed over-the-counter). The company maintains its research and development operations in France while engaging global partners to advance clinical trials and commercialization efforts. Under the leadership of Chief Executive Officer Pascal Brandel, Adocia continues to pursue regulatory milestones and strategic alliances aimed at bringing next-generation metabolic therapies to market.

Key Stats

• Today's Range: C$8.87 to C$8.87
• 50-Day Range: C$8.87 to C$8.87
• 52-Week Range: C$8.87 to C$11.24
• Volume: N/A
• Average Volume: 2,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ADOIF
• CIK: N/A
• Web: www.adocia.com
• Phone: 33 4 72 61 06 10
• Fax: N/A
• Employees: 97
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A